Urinary neutrophil gelatinase-associated lipocalin for early detection of acute kidney injury in geriatric patients with urinary tract infection treated by colistin

Clinical Nephrology

Volumn 80, Issue 6, 2013, Pages 405-416

  Shavit, Linda ^a   Manilov, Rackhel ^a   Wiener Well, Yonit ^a   Algur, Nurit ^a   Slotki, Itzchak ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Acute kidney injury; Colistin; Neutrophil gelatinaseassociated lipocalin; Urinary tract infection

Indexed keywords

COLISTIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ACUTE PHASE PROTEIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; AGED; ANEMIA; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COMORBIDITY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; EARLY DIAGNOSIS; ERYTHROCYTE COUNT; FEMALE; FLUID RESUSCITATION; GERIATRIC PATIENT; HEART FAILURE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; INDWELLING URINARY CATHETER; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LEUKOCYTE; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; UREMIA; URINALYSIS; URINARY TRACT INFECTION; URINE CULTURE; URINE LEVEL; VERY ELDERLY; ACUTE KIDNEY INJURY; URINARY TRACT INFECTIONS; URINE;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; COLISTIN; EARLY DIAGNOSIS; FEMALE; HUMANS; LIPOCALINS; MALE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; URINARY TRACT INFECTIONS;

EID: 84896589138     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107974     Document Type: Article

References (65)

1. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006; 10: R27. CrossRef PubMed
2. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrugresistant gram-negative bacterial infections. Clin Infect Dis. 2005; 40: 1333-1341. Erratum in: Clin Infect Dis. 2006; 42: 1819. Dosage error in article text. CrossRef PubMed
3. Falagas ME, Rafailidis PI. Nephrotoxicity of colistin: new insight into an old antibiotic. Clin Infect Dis. 2009; 48: 1729-1731.CrossRef PubMed [4] Coliracin injectionM (colistin sulphomethate) parenteral [package insert]. Rafa Laboratories Ltd., Israel. 2005.
4. Coliracin injectionM (colistin sulphomethate) parenteral [package insert]. Rafa Laboratories Ltd., Israel. 2005.
5. Colomycin (colistimethate sodium) [package insert]. Bexley. United Kingdom: Forest Laboratories, 2002.
6. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970; 72: 857-868.CrossRef PubMed
7. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009; 48: 1724-1728.CrossRef PubMed
8. Bellomo R, Kellum JA, Ronco C. Defining acute renal failure: physiological principles. Intensive Care Med. 2004; 30: 33-37.CrossRef PubMed
9. Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993; 268: 10425-10432. PubMed
10. Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics. 1997; 45: 17-23. CrossRef PubMed
11. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P. Neutrophil gelatinase- associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005; 365: 1231-1238.CrossRef PubMed
12. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S. Neutrophil-gelatinase- associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol. 2006; 26: 287-292.CrossRef PubMed
13. Hirsch R, Dent C, Pfriem H, Allen J, Beekman RH III, Ma Q, Dastrala S, Bennett M, Mitsnefes M, Devarajan P. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol. 2007; 22: 2089-2095. CrossRef PubMed
14. Ling W, Zhaohui N, Ben H, Leyi G, Jianping L, Huili D, Jiaqi Q. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract. 2008; 108: c176-c181.CrossRef PubMed
15. Wheeler DS, Devarajan P, Ma Q, Harmon K, Monaco M, Cvijanovich N, Wong HR. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. Crit Care Med. 2008; 36: 1297-1303.CrossRef PubMed
16. Nickolas TL, O'Rourke MJ, Yang J, Sise ME, Canetta PA, Barasch N, Buchen C, Khan F, Mori K, Giglio J, Devarajan P, Barasch J. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med. 2008; 148: 810-819.Cross- Ref PubMed
17. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute Kidney Injury Network: Acute Kidney Injury Network: report of an initiative to improve outcomes inacute kidney injury. Crit Care. 2007; 11: R31CrossRef PubMed
18. ARCHITECT Urine NGAL assay, Abbott Laboratories, Diagnostic Division, July 2009
19. Siew ED, Ware LB, Gebretsadik T, Shintani A, Moons KGM, Wickersham N, Bossert F, Ikizler TA. Urine neutrophil gelatinase-associated lipocalin moderately predicts acute kidney injury in critically ill adults. J Am Soc Nephrol. 2009; 20: 1823-1832.CrossRef PubMed
20. Haase-Fielitz A, Bellomo R, Devarajan P, Bennett M, Story D, Matalanis G, Frei U, Dragun D, Haase M. The predictive performance of plasma neutrophil gelatinase-associated lipocalin (NGAL) increases with grade of acute kidney injury. Nephrol Dial Transplant. 2009; 24: 3349-3354. CrossRef PubMed
21. Sengeløv H, Boulay F, Kjeldsen L, Borregaard N. Subcellular localization and translocation of the receptor for N-formylmethionyl-leucyl-phenylalanine in human neutrophils. Biochem J. 1994; 299: 473-479. PubMed
22. Xu SY, Pauksen K, Venge P. Serum measurements of human neutrophil lipocalin (HNL) discriminate between acute bacterial and viral infections. Scand J Clin Lab Invest. 1995; 55: 125-131. CrossRef PubMed
23. Chan YR, Liu JS, Pociask DA, Zheng M, Mietzner TA, Berger T, Mak TW, Clifton MC, Strong RK, Ray P, Kolls JK. Lipocalin 2 is required for pulmonary host defense against Klebsiella infection. J Immunol. 2009; 182: 4947-4956.CrossRef PubMed
24. Yilmaz A, Sevketoglu E, Gedikbasi A, Karyagar S, Kiyak A, Mulazimoglu M, Aydogan G, Ozpacaci T, Hatipoglu S. Early prediction of urinary tract infection with urinary neutrophil gelatinase associated lipocalin. Pediatr Nephrol. 2009; 24: 2387- 2392.CrossRef PubMed
25. Cai L, Rubin J, Han W, Venge P, Xu S. The origin of multiple molecular forms in urine of HNL/ NGAL. Clin J Am Soc Nephrol. 2010; 5: 2229- 2235.CrossRef PubMed
26. McWilliam SJ, Antoine DJ, Sabbisetti V, Turner MA, Farragher T, Bonventre JV, Park BK, Smyth RL, Pirmohamed M. Mechanism-based urinary biomarkers to identify the potential for aminoglycoside- induced nephrotoxicity in premature neonates: a proof-of-concept study. PLoS ONE. 2012; 7: e43809.CrossRef PubMed
27. Gaspari F, Cravedi P, Mandalà M, Perico N, de Leon FR, Stucchi N, Ferrari S, Labianca R, Remuzzi G, Ruggenenti P. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase- associated lipocalin excretion: a pilot prospective case-control study. Nephron Clin Pract. 2010; 115: c154-c160.CrossRef PubMed
28. Hoffmann D, Fuchs TC, Henzler T, Matheis KA, Herget T, Dekant W, Hewitt P, Mally A. Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity. Toxicology. 2010; 277: 49-58. PubMed
29. Nykjaer A, Schambye H, Pedersen AH, Nielsen H. Assessing low-dose gentamicin-induced kidney injury in rats by analysis of urine. J Pharmacol Toxicol Methods. 2009; 60: 316-320.CrossRef PubMed
30. Kai K, Yamaguchi T, Yoshimatsu Y, Kinoshita J, Teranishi M, Takasaki W. Neutrophil gelatinaseassociated lipocalin, a sensitive urinary biomarker of acute kidney injury in dogs receiving gentamicin. J Toxicol Sci. 2013; 38: 269-277.CrossRef PubMed
31. Sasaki D, Yamada A, Umeno H, Kurihara H, Nakatsuji S, Fujihira S, Tsubota K, Ono M, Moriguchi A, Watanabe K, Seki J. Comparison of the course of biomarker changes and kidney injury in a rat model of drug-induced acute kidney injury. Biomarkers. 2011; 16: 553-566.CrossRef PubMed
32. Sinha V, Vence LM, Salahudeen AK. Urinary tubular protein-based biomarkers in the rodent model of cisplatin nephrotoxicity: a comparative analysis of serum creatinine, renal histology, and urinary KIM-1, NGAL, and NAG in the initiation, maintenance, and recovery phases of acute kidney injury. J Investig Med. 2013; 61: 564-568. PubMed
33. Sohn SJ, Kim SY, Kim HS, Chun YJ, Han SY, Kim SH, Moon A. In vitro evaluation of biomarkers for cisplatin-induced nephrotoxicity using HK-2 human kidney epithelial cells. Toxicol Lett. 2013; 217: 235-242. PubMed
34. Fuchs TC, Frick K, Emde B, Czasch S, von Landenberg F, Hewitt P. Evaluation of novel acute urinary rat kidney toxicity biomarker for subacute toxicity studies in preclinical trials. Toxicol Pathol. 2012; 40: 1031-1048.CrossRef PubMed
35. Tonomura Y, Tsuchiya N, Torii M, Uehara T. Evaluation of the usefulness of urinary biomarkers for nephrotoxicity in rats. Toxicology. 2010; 273: 53-59. PubMed
36. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol. 2004; 24: 307-315.CrossRef PubMed
37. Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect. 2012; 18: 18-29.CrossRef PubMed
38. Reina R, Estenssoro E, Sáenz G, Canales HS, Gonzalvo R, Vidal G, Martins G, Das Neves A, Santander O, Ramos C. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med. 2005; 31: 1058-1065.CrossRef PubMed
39. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, Hamida CB, Chaari A, Rekik N, Bouaziz M. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator- associated pneumonia: a matched case-control study. Intensive Care Med. 2007; 33: 1162-1167. CrossRef PubMed
40. Hachem RY, Chemaly RF, Ahmar CA, Jiang Y, Boktour MR, Rjaili GA, Bodey GP, Raad II. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother. 2007; 51: 1905-1911.CrossRef PubMed
41. Rios FG, Luna CM, Maskin B, Saenz Valiente A, Lloria M, Gando S, Sosa C, Baquero S, Llerena C, Petrati C, Apezteguia C. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J. 2007; 30: 307-313. CrossRef PubMed
42. Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis. 2007; 11: 402-406.CrossRef PubMed
43. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother. 2008; 61: 1369-1375.Cross- Ref PubMed
44. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/ sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect. 2008; 56: 432-436.CrossRef PubMed
45. Gounden R, Bamford C, van Zyl-Smit R, Cohen K, Maartens G. Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis. 2009; 9: 26CrossRef PubMed
46. Durakovic N, Radojcic V, Boban A, Mrsic M, Sertic D, Serventi-Seiwerth R, Nemet D, Labar B. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med. 2011; 50: 1009-1013.CrossRef PubMed
47. Lim SK, Lee SO, Choi SH, Choi J-P, Kim S-H, Jeong J-Y, Choi S-H, Woo JH, Kim YS. The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections. J Korean Med Sci. 2011; 26: 325-331. CrossRef PubMed
48. Kvitko CH, Rigatto MH, Moro AL, Zavascki AP. Polymyxin B versus other antimicrobials for the treatment of pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother. 2011; 66: 175-179. CrossRef PubMed
49. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother. 2003; 47: 2659-2662.CrossRef PubMed
50. Paul M, Bishara J, Levcovich A, Chowers M, Goldberg E, Singer P, Lev S, Leon P, Raskin M, Yahav D, Leibovici L. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother. 2010; 65: 1019-1027. CrossRef PubMed
51. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis. 2005; 5: 1CrossRef PubMed
52. Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis. 2006; 25: 596-599.CrossRef PubMed
53. Pintado V, San Miguel LG, Grill F, Mejía B, Cobo J, Fortún J, Martín-Dávila P, Moreno S. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect. 2008; 56: 185-190.Cross- Ref PubMed
54. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug- resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2010; 35: 297-300. CrossRef PubMed
55. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents. 2005; 26: 504-507.CrossRef PubMed
56. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother. 2010; 54: 4503-4505.CrossRef PubMed
57. Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents. 2009; 34: 434-438. CrossRef PubMed
58. Ko Hj, Jeon Mh, Choo Ej, Lee Ej, Kim Th, Jun J-B, Gil H-W. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract. 2011; 117: c284- c288.CrossRef PubMed
59. Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect. 2011; 62: 187-190.CrossRef PubMed
60. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011; 53: 879-884.CrossRef PubMed
61. Nation RL, Li J. Optimizing use of colistin and polymyxin B in the critically ill. Semin Respir Crit Care Med. 2007; 28: 604-614.CrossRef PubMed
62. Foxman B, Brown P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am. 2003; 17: 227-241.CrossRef PubMed
63. Juthani-Mehta M. Asymptomatic bacteriuria and urinary tract infection in older adults. Clin Geriatr Med. 2007; 23: 585-594., viiCrossRef PubMed
64. Tal S, Guller V, Levi S, Bardenstein R, Berger D, Gurevich I, Gurevich A. Profile and prognosis of febrile elderly patients with bacteremic urinary tract infection. J Infect. 2005; 50: 296-305.Cross- Ref PubMed
65. Decavele AS, Dhondt L, De Buyzere ML, Delanghe JR. Increased urinary neutrophil gelatinase associated lipocalin in urinary tract infections and leukocyturia. Clin Chem Lab Med. 2011; 49: 999- 1003.CrossRef PubMed